ArticleJournal of psychopharmacology (Oxford, England)2025

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program.

Jolien Ke Veraart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.